Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma

This study is testing a new type of cell therapy — chimeric natural killer receptor-universal T cells (CNKR-T cells) — for children with neuroblastoma (a childhood cancer of the nervous system) that has come back or stopped responding to standard treatments. This is an innovative approach where engineered immune cells are used to attack the cancer. **You may be eligible if...** - Your child is between 1 and 12 years old and weighs at least 10 kg - Your child has been diagnosed with relapsed or refractory neuroblastoma (cancer that returned after or never responded to standard treatment) - A guardian or the child (if applicable) can sign the informed consent **You may NOT be eligible if...** - Your child is under 1 year old or weighs less than 10 kg - Your child does not have a confirmed diagnosis of relapsed or refractory neuroblastoma - Your child has significant health conditions that would make the cell therapy unsafe - Your child has not received adequate prior standard treatments Talk to your doctor to see if this trial is right for you.